December 15, 2016
(New York Times) – The attorneys general in 20 states on Thursday accused six generic pharmaceutical companies, including the industry giants Teva and Mylan, of a scheme to artificially inflate the prices of an antibiotic and a diabetes drug. The state officials said the charges were part of a broad investigation into potential price-fixing within the industry, suggesting that more charges could follow. The investigation, at the state and federal levels, has left a cloud of uncertainty over the industry, which has also been under a barrage of public criticism about its pricing methods.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.